In December, Novo Nordisk (NYSE:NVO) submitted a new drug application to the FDA for a 2.4-mg dose of subcutaneous semaglutide for chronic weight management
Consistent Eating Patterns Regular meal timing prevents under-eating and maintains steady energy levels
Betacarophylline, a cannabinoid receptor agonist, contributes to pain relief and nerve protection
Semaglutide helps decrease these cravings, making it easier to make healthier food choices
Baseline factors including age, hydration habits, fiber intake, existing IBS history, medications (opioids, anticholinergics), and genetic variants in GI peptide pathways all influence susceptibility
Although these options offer various benefits and incredible outcomes, there are possible risks over time